FDA finds 3 COVID-19 tests that fail to detect omicron variant

 

• FDA has identified three COVID-19 molecular tests that are not able to detect the omicron variant and warned that the diagnostics from Applied DNA Sciences, Meridian Bioscience and Tide Laboratories will return false negative results.
• The agency on Wednesday updated its list of tests impacted by virus mutations. While FDA continues to gather additional information and work with the three manufacturers to address these issues, it recommended the diagnostics not be used by clinical laboratory staff and healthcare providers.
• Makers of both polymerase chain reaction and rapid antigen tests have said their tests can detect omicron. Siemens Healthineers is the latest company to claim its testing portfolio is unaffected by the variant. However, Tim Stenzel, director of the FDA's Office of In Vitro Diagnostics and Radiological Health, told test developers Wednesday during a virtual town hall that the agency continues to receive "a lot of inquiries" about omicron and its potential impact on diagnostics and will continue to focus efforts on evaluating molecular and antigen tests.

As omicron continues to spread worldwide, public health experts contend it's critical that currently available COVID-19 tests are able to detect the variant and work as well as they did in detecting other strains such as delta. However, mutations in the viral targets of some tests could result in false negative results, according to FDA.

"Clinical laboratory staff and healthcare providers should be aware that false negative results may occur with any molecular test for the detection of SARS-CoV-2, particularly if a mutation occurs in the part of the virus' genome assessed by that test," FDA's website states.

Following a preliminary review, FDA announced in late November that it expected PCR and rapid antigen tests used in the U.S. to be able to detect the omicron variant. However, the agency now says three diagnostics are "expected to fail to detect the SARS-CoV-2 omicron variant" and they should not be used until the issues are resolved.

FDA noted on its website that Tide's DTPM COVID-19 RT-PCR test is currently being performed in the U.S. by more than 30 laboratories, providing the names and cities where the labs are located, but added that the diagnostic "is not believed to be used for high volume testing."

In the case of Meridian Bioscience's Revogene SARS-CoV-2 test, FDA said that the company has not yet distributed the diagnostic and does not intend to do so inside or outside the U.S. until the issue is resolved. No information on the current use of Applied DNA Sciences' Linea COVID-19 Assay Kit is provided by the agency's website.

The Applied DNA Sciences is the first two-viral target assay to fail to detect omicron. Meridian's and Tide's diagnostics are both single-target tests.

"Fortunately, we think that these [three tests] are still relatively low abundance, relatively low volume," Stenzel told test developers Wednesday, noting that FDA continues to monitor viral mutations and variants and the potential impact on COVID-19 diagnostics and serology tests.

Stenzel warned that FDA believes omicron "is going to be a significant variant in the U.S. in very short order."

FDA will update its website "as new and important information is gleaned" regarding potential impacts on COVID-19 tests, Stenzel said. "Sometimes we'll do something out of an abundance of caution, others we will update for information that we think is critical," Stenzel added.

The agency's evaluation of antigen tests continues, Stenzel said, and "is dependent on both developers and/or the U.S. government actually acquiring omicron samples and being able to test them in the lab."

https://www.healthcaredive.com/news/fda-update-covid-tests-fail-detect-omicron-variant/611666/